FIELD: biochemistry.
SUBSTANCE: invention relates to a humanized antibody which specifically binds to a human transferrin receptor. Also disclosed are the shuttle module and the pharmaceutical composition containing said antibodies. Disclosed is a method of treating using said shuttle module and using said shuttle module antibody.
EFFECT: invention provides effective treatment of neurological disorder.
16 cl, 14 ex, 6 tbl, 3 dwg
| Title | Year | Author | Number |
|---|---|---|---|
| BISPECIFIC ANTIBODIES TO HUMAN BETA-AMYLOID / HUMAN TRANSFERRIN RECEPTOR AND METHODS OF USING THEM | 2016 |
|
RU2730682C1 |
| ANTIBODIES AGAINST FOLIC ACID RECEPTOR 1, THEIR IMMUNOCONJUGATES AND USE | 2011 |
|
RU2740479C2 |
| TETANUS TOXIN ANTIBODY AND USE THEREOF | 2020 |
|
RU2815280C1 |
| ANTIBODIES AGAINST PD-L1 AND THEIR OPTIONS | 2017 |
|
RU2770590C2 |
| ANTI-HLA-A2 ANTIBODIES AND THEIR APPLICATION METHODS | 2018 |
|
RU2782276C2 |
| ANTIBODY BINDING HUMAN IL-4R, ANTIGEN-BINDING FRAGMENT THEREOF, AND MEDICAL APPLICATION THEREOF | 2019 |
|
RU2779649C1 |
| ANTIBODY TO IL-13RA2 AND ITS APPLICATION | 2018 |
|
RU2756623C2 |
| MONOCLONAL BINDING AGENTS, THEIR DRUG CONJUGATES AND THEIR APPLICATIONS | 2017 |
|
RU2744914C2 |
| BISPECIFIC MOLECULES, IMMUNOREACTIVE WITH IMMUNE EFFECTOR CELLS EXPRESSING AN ACTIVATING RECEPTOR | 2014 |
|
RU2721707C2 |
| PHARMACEUTICAL COMPOSITION OF THE FUSION PROTEIN OF THE TRANSFORMING GROWTH FACTOR BETA RECEPTOR AND ITS APPLICATION | 2019 |
|
RU2791683C2 |
